Literature DB >> 31634051

Yellow fever virus: historical and current issues regarding recent epidemics and vaccination in Brazil.

Ricardo Ishak1, Marluísa de Oliveira Guimarães Ishak1, Antonio Carlos R Vallinoto1, Francisco De Paula Pinheiro1,2.   

Abstract

Yellow fever has been recently described in nonurban areas of Brazil despite 80 years of commercial vaccine use. Although the disease does not spread fear in the general population as it did in the past, yellow fever virus continues to cause many cases of severe disease. Persistence of the virus in the host is a new mechanism to be considered in the pathology of the disease. Immunization with a fractional dose of vaccine during emergency situations needs to be evaluated for antibody duration, and new and improved vaccines should be considered.

Entities:  

Keywords:  YF vaccine; YFV persistence; Yellow fever virus

Year:  2019        PMID: 31634051      PMCID: PMC7227728          DOI: 10.1080/21645515.2019.1678359

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  18 in total

1.  Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine.

Authors:  H GROOT; R B RIBERIRO
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

2.  The thermal stability of yellow fever vaccines.

Authors:  R Ishak; C R Howard
Journal:  Mem Inst Oswaldo Cruz       Date:  1990 Jul-Sep       Impact factor: 2.743

3.  Yellow fever vaccine: WHO position on the use of fractional doses – June 2017.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-06-23

4.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

5.  Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.

Authors:  P F Vasconcelos; E J Luna; R Galler; L J Silva; T L Coimbra; V L Barros; T P Monath; S G Rodigues; C Laval; Z G Costa; M F Vilela; C L Santos; P M Papaiordanou; V A Alves; L D Andrade; H K Sato; E S Rosa; G B Froguas; E Lacava; L M Almeida; A C Cruz; I M Rocco; R T Santos; O F Oliva; C M Papaiordanou
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

6.  The Rockefeller Foundation virus program: 1951-1971 with update to 1981.

Authors:  W G Downs
Journal:  Annu Rev Med       Date:  1982       Impact factor: 13.739

7.  Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.

Authors:  Rebecca M Casey; Jennifer B Harris; Steve Ahuka-Mundeke; Meredith G Dixon; Gabriel M Kizito; Pierre M Nsele; Grace Umutesi; Janeen Laven; Olga Kosoy; Gilson Paluku; Abdou S Gueye; Terri B Hyde; Raimi Ewetola; Guylain K M Sheria; Jean-Jacques Muyembe-Tamfum; J Erin Staples
Journal:  N Engl J Med       Date:  2018-02-14       Impact factor: 91.245

8.  Fractional-Dose Yellow Fever Vaccination - Advancing the Evidence Base.

Authors:  Kirsten Vannice; Annelies Wilder-Smith; Joachim Hombach
Journal:  N Engl J Med       Date:  2018-07-11       Impact factor: 91.245

Review 9.  Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation.

Authors:  Cristina Possas; Ricardo Lourenço-de-Oliveira; Pedro Luiz Tauil; Francisco de Paula Pinheiro; Alcides Pissinatti; Rivaldo Venâncio da Cunha; Marcos Freire; Reinaldo Menezes Martins; Akira Homma
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-09-03       Impact factor: 2.743

10.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.